Table of Content

Chapter 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
Chapter 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
Chapter 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Increase in incidence of gastric cancer
3.4.1.2. Advancements in diagnostic technologies
3.4.1.3. Growing awareness about gastric cancer
3.4.2. Restraints
3.4.2.1. High diagnostic cost
3.4.3. Opportunities
3.4.3.1. Significant unmet need in cancer diagnosis
3.4.3.2. Growth opportunities in emerging markets
Chapter 4: GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT
4.1. Overview
4.1.1. Market size and forecast
4.2. Reagents and Consumables
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Instruments
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
Chapter 5: GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Adenocarcinoma
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Gastric Lymphoma
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
Chapter 6: GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Diagnostic Laboratories
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Diagnostic Imaging Centers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
Chapter 7: GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key market trends, growth factors and opportunities
7.2.2. Market size and forecast, by Product
7.2.3. Market size and forecast, by Disease Type
7.2.4. Market size and forecast, by End User
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Market size and forecast, by Product
7.2.5.1.2. Market size and forecast, by Disease Type
7.2.5.1.3. Market size and forecast, by End User
7.2.5.2. Canada
7.2.5.2.1. Market size and forecast, by Product
7.2.5.2.2. Market size and forecast, by Disease Type
7.2.5.2.3. Market size and forecast, by End User
7.2.5.3. Mexico
7.2.5.3.1. Market size and forecast, by Product
7.2.5.3.2. Market size and forecast, by Disease Type
7.2.5.3.3. Market size and forecast, by End User
7.3. Europe
7.3.1. Key market trends, growth factors and opportunities
7.3.2. Market size and forecast, by Product
7.3.3. Market size and forecast, by Disease Type
7.3.4. Market size and forecast, by End User
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Market size and forecast, by Product
7.3.5.1.2. Market size and forecast, by Disease Type
7.3.5.1.3. Market size and forecast, by End User
7.3.5.2. France
7.3.5.2.1. Market size and forecast, by Product
7.3.5.2.2. Market size and forecast, by Disease Type
7.3.5.2.3. Market size and forecast, by End User
7.3.5.3. UK
7.3.5.3.1. Market size and forecast, by Product
7.3.5.3.2. Market size and forecast, by Disease Type
7.3.5.3.3. Market size and forecast, by End User
7.3.5.4. Italy
7.3.5.4.1. Market size and forecast, by Product
7.3.5.4.2. Market size and forecast, by Disease Type
7.3.5.4.3. Market size and forecast, by End User
7.3.5.5. Spain
7.3.5.5.1. Market size and forecast, by Product
7.3.5.5.2. Market size and forecast, by Disease Type
7.3.5.5.3. Market size and forecast, by End User
7.3.5.6. Rest of Europe
7.3.5.6.1. Market size and forecast, by Product
7.3.5.6.2. Market size and forecast, by Disease Type
7.3.5.6.3. Market size and forecast, by End User
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors and opportunities
7.4.2. Market size and forecast, by Product
7.4.3. Market size and forecast, by Disease Type
7.4.4. Market size and forecast, by End User
7.4.5. Market size and forecast, by country
7.4.5.1. Japan
7.4.5.1.1. Market size and forecast, by Product
7.4.5.1.2. Market size and forecast, by Disease Type
7.4.5.1.3. Market size and forecast, by End User
7.4.5.2. China
7.4.5.2.1. Market size and forecast, by Product
7.4.5.2.2. Market size and forecast, by Disease Type
7.4.5.2.3. Market size and forecast, by End User
7.4.5.3. India
7.4.5.3.1. Market size and forecast, by Product
7.4.5.3.2. Market size and forecast, by Disease Type
7.4.5.3.3. Market size and forecast, by End User
7.4.5.4. Australia
7.4.5.4.1. Market size and forecast, by Product
7.4.5.4.2. Market size and forecast, by Disease Type
7.4.5.4.3. Market size and forecast, by End User
7.4.5.5. South Korea
7.4.5.5.1. Market size and forecast, by Product
7.4.5.5.2. Market size and forecast, by Disease Type
7.4.5.5.3. Market size and forecast, by End User
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Market size and forecast, by Product
7.4.5.6.2. Market size and forecast, by Disease Type
7.4.5.6.3. Market size and forecast, by End User
7.5. LAMEA
7.5.1. Key market trends, growth factors and opportunities
7.5.2. Market size and forecast, by Product
7.5.3. Market size and forecast, by Disease Type
7.5.4. Market size and forecast, by End User
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Market size and forecast, by Product
7.5.5.1.2. Market size and forecast, by Disease Type
7.5.5.1.3. Market size and forecast, by End User
7.5.5.2. Saudi Arabia
7.5.5.2.1. Market size and forecast, by Product
7.5.5.2.2. Market size and forecast, by Disease Type
7.5.5.2.3. Market size and forecast, by End User
7.5.5.3. South Africa
7.5.5.3.1. Market size and forecast, by Product
7.5.5.3.2. Market size and forecast, by Disease Type
7.5.5.3.3. Market size and forecast, by End User
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Market size and forecast, by Product
7.5.5.4.2. Market size and forecast, by Disease Type
7.5.5.4.3. Market size and forecast, by End User
Chapter 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product mapping of top 10 player
8.4. Competitive dashboard
8.5. Competitive heatmap
8.6. Top player positioning, 2022
Chapter 9: COMPANY PROFILES
9.1. Bio-Rad Laboratories, Inc. 
9.1.1. Company overview
9.1.2. Key executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. Qiagen NV.
9.2.1. Company overview
9.2.2. Key executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.2.7. Key strategic moves and developments
9.3. Agilent Technologies, Inc.
9.3.1. Company overview
9.3.2. Key executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.3.7. Key strategic moves and developments
9.4. MiRXES Pte Ltd
9.4.1. Company overview
9.4.2. Key executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Key strategic moves and developments
9.5. Hipro Biotechnology Co.,Ltd.
9.5.1. Company overview
9.5.2. Key executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.6. Fulgent Genetics
9.6.1. Company overview
9.6.2. Key executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Exact Sciences Corporation
9.7.1. Company overview
9.7.2. Key executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.7.7. Key strategic moves and developments
9.8. Endofotonics Pte Ltd
9.8.1. Company overview
9.8.2. Key executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.9. Abbott Laboratories
9.9.1. Company overview
9.9.2. Key executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.10. F. Hoffmann-La Roche Ltd.
9.10.1. Company overview
9.10.2. Key executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance



List of Figures

LIST OF FIGURES
FIGURE 01. GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF GASTRIC CANCER DIAGNOSTIC MARKET,2022-2032
FIGURE 03. TOP IMPACTING FACTORS IN GASTRIC CANCER DIAGNOSTIC MARKET (2022 TO 2032)
FIGURE 04. TOP INVESTMENT POCKETS IN GASTRIC CANCER DIAGNOSTIC MARKET (2023-2032)
FIGURE 05. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 06. MODERATE THREAT OF NEW ENTRANTS
FIGURE 07. MODERATE THREAT OF SUBSTITUTES
FIGURE 08. MODERATE INTENSITY OF RIVALRY
FIGURE 09. MODERATE BARGAINING POWER OF BUYERS
FIGURE 10. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR REAGENTS AND CONSUMABLES, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR ADENOCARCINOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR GASTRIC LYMPHOMA, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022 AND 2032(%)
FIGURE 19. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY COUNTRY 2022 AND 2032(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. GASTRIC CANCER DIAGNOSTIC MARKET BY REGION, 2022 AND 2032(%)
FIGURE 23. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 24. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 25. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 26. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 27. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 28. UK GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 29. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 30. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 31. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 32. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 34. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 35. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 36. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 37. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 38. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 39. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 40. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 41. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, 2022-2032 ($MILLION)
FIGURE 42. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 43. COMPETITIVE DASHBOARD
FIGURE 44. COMPETITIVE HEATMAP: GASTRIC CANCER DIAGNOSTIC MARKET
FIGURE 45. TOP PLAYER POSITIONING, 2022
FIGURE 46. BIO-RAD LABORATORIES, INC.?: NET SALES, 2020-2022 ($MILLION)
FIGURE 47. BIO-RAD LABORATORIES, INC.?: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 48. BIO-RAD LABORATORIES, INC.?: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 49. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 50. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 51. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. AGILENT TECHNOLOGIES, INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 53. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. AGILENT TECHNOLOGIES, INC.: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. EXACT SCIENCES CORPORATION: NET REVENUE, 2019-2021 ($MILLION)
FIGURE 56. EXACT SCIENCES CORPORATION: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 57. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
FIGURE 58. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 59. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 60. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 61. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)

List of Tables

LIST OF TABLES
TABLE 01. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 02. GASTRIC CANCER DIAGNOSTIC MARKET FOR REAGENTS AND CONSUMABLES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GASTRIC CANCER DIAGNOSTIC MARKET FOR INSTRUMENTS, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 05. GASTRIC CANCER DIAGNOSTIC MARKET FOR ADENOCARCINOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GASTRIC CANCER DIAGNOSTIC MARKET FOR GASTRIC LYMPHOMA, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GASTRIC CANCER DIAGNOSTIC MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. GLOBAL GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 09. GASTRIC CANCER DIAGNOSTIC MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GASTRIC CANCER DIAGNOSTIC MARKET FOR DIAGNOSTIC IMAGING CENTERS, BY REGION, 2022-2032 ($MILLION)
TABLE 12. GASTRIC CANCER DIAGNOSTIC MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 13. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 14. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 15. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 17. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 18. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 19. U.S. GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 20. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 21. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 22. CANADA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 24. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 25. MEXICO GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 27. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 28. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 30. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 31. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 32. GERMANY GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 33. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 34. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 35. FRANCE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 37. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 38. UK GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 40. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 41. ITALY GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 43. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 44. SPAIN GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 46. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 47. REST OF EUROPE GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 49. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 50. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 52. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 53. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 54. JAPAN GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 55. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 56. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 57. CHINA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 59. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 60. INDIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 62. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 63. AUSTRALIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 65. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 66. SOUTH KOREA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 68. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 69. REST OF ASIA-PACIFIC GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 71. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 72. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 74. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 75. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 76. BRAZIL GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 77. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 78. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 79. SAUDI ARABIA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 81. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 82. SOUTH AFRICA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY PRODUCT, 2022-2032 ($MILLION)
TABLE 84. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY DISEASE TYPE, 2022-2032 ($MILLION)
TABLE 85. REST OF LAMEA GASTRIC CANCER DIAGNOSTIC MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. BIO-RAD LABORATORIES, INC.?: KEY EXECUTIVES
TABLE 87. BIO-RAD LABORATORIES, INC.?: COMPANY SNAPSHOT
TABLE 88. BIO-RAD LABORATORIES, INC.?: PRODUCT SEGMENTS
TABLE 89. BIO-RAD LABORATORIES, INC.?: PRODUCT PORTFOLIO
TABLE 90. QIAGEN NV.: KEY EXECUTIVES
TABLE 91. QIAGEN NV.: COMPANY SNAPSHOT
TABLE 92. QIAGEN NV.: PRODUCT SEGMENTS
TABLE 93. QIAGEN NV.: PRODUCT PORTFOLIO
TABLE 94. QIAGEN NV.: KEY STRATERGIES
TABLE 95. AGILENT TECHNOLOGIES, INC.: KEY EXECUTIVES
TABLE 96. AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE 97. AGILENT TECHNOLOGIES, INC.: PRODUCT SEGMENTS
TABLE 98. AGILENT TECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE 99. AGILENT TECHNOLOGIES, INC.: KEY STRATERGIES
TABLE 100. MIRXES PTE LTD: KEY EXECUTIVES
TABLE 101. MIRXES PTE LTD: COMPANY SNAPSHOT
TABLE 102. MIRXES PTE LTD: PRODUCT SEGMENTS
TABLE 103. MIRXES PTE LTD: PRODUCT PORTFOLIO
TABLE 104. MIRXES PTE LTD: KEY STRATERGIES
TABLE 105. HIPRO BIOTECHNOLOGY CO.,LTD.: KEY EXECUTIVES
TABLE 106. HIPRO BIOTECHNOLOGY CO.,LTD.: COMPANY SNAPSHOT
TABLE 107. HIPRO BIOTECHNOLOGY CO.,LTD.: PRODUCT SEGMENTS
TABLE 108. HIPRO BIOTECHNOLOGY CO.,LTD.: PRODUCT PORTFOLIO
TABLE 109. FULGENT GENETICS: KEY EXECUTIVES
TABLE 110. FULGENT GENETICS: COMPANY SNAPSHOT
TABLE 111. FULGENT GENETICS: PRODUCT SEGMENTS
TABLE 112. FULGENT GENETICS: PRODUCT PORTFOLIO
TABLE 113. EXACT SCIENCES CORPORATION: KEY EXECUTIVES
TABLE 114. EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT
TABLE 115. EXACT SCIENCES CORPORATION: PRODUCT SEGMENTS
TABLE 116. EXACT SCIENCES CORPORATION: PRODUCT PORTFOLIO
TABLE 117. EXACT SCIENCES CORPORATION: KEY STRATERGIES
TABLE 118. ENDOFOTONICS PTE LTD: KEY EXECUTIVES
TABLE 119. ENDOFOTONICS PTE LTD: COMPANY SNAPSHOT
TABLE 120. ENDOFOTONICS PTE LTD: PRODUCT SEGMENTS
TABLE 121. ENDOFOTONICS PTE LTD: PRODUCT PORTFOLIO
TABLE 122. ABBOTT LABORATORIES: KEY EXECUTIVES
TABLE 123. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 124. ABBOTT LABORATORIES: PRODUCT SEGMENTS
TABLE 125. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
TABLE 126. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
TABLE 127. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
TABLE 128. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
TABLE 129. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO